tbuckley/cabot-search huggingface dataset:
PATIENTS THAT RESPOND TO ENHANCED EXTERNAL COUNTERPULSATION ARE AT DECREASED RISK FOR MAJOR ADVERSE CARDIAC EVENTS AND HAVE INCREASES IN ENDOTHELIAL PRECURSOR STEM CELLS
Authors: Joseph Tartaglia, Edmund Timpano, Kate Steinberg, Christina Tartaglia, Joseph DeMarco, Gregory Puccio, Maxim Gersh, Catie Dire, Carol A. Eisenberg, Carl V. Hamby
Journal: Journal of the American College of Cardiology (2015)
DIEZ AÑOS DE SEGUIMIENTO DE TUMORES VELLOSOS RESECADOS ENDOSCOPICAMENTE
Authors: B García Perez, R García Paredes, JA Pons Miñano, M Miras Lopez, MC Garre Sánchez, M Muñoz Tornero, E Estrella Diez, A Serrano Jimenez, M Alajarin Cervera, LF Carballo Alvarez
Journal: Endoscopy (2011)

Objetivo: Valorar el índice de recidivas, de tumores vellosos (mayores de 4cm, sésil, se excluían los pediculados, de diferentes morfologías) después de 10 años de seguimiento.
“Quasi-Symmetric” FDG Avidity of Bilateral Salivary Glands in Mikulicz Disease Yielding False-Positive Staging in Lung Cancer
Authors: Li-Fan Lin, Daniel HY Shen, Wen-Chiuan Tsai, Cheng-Han Hou, Cheng-Yi Cheng, Ching-Yuan Chen
Journal: Clinical Nuclear Medicine (2012)

A 77-year-old man with lung cancer underwent fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). Cervical FDG uptake of variable intensity was detected corresponding to enlarged masses in the bilateral parotid and left submandibular regions. We suspected metastases from primary lung cancer or coexisting salivary gland neoplasms. Histopathological examination of the FDG-avid parotid mass revealed Mikulicz disease, an uncommon autoimmune disease involving the salivary glands. We present this case of Mikulicz disease with "quasi-symmetric" FDG avidity in the major salivary glands. We believe that salivary FDG uptake can lead to erroneous interpretation of tumor staging using PET.
A2.9 Novel role for galectin-1 in T-cell apoptosis regulation and ist relevance to systemic lupus erythematosus
Authors: A Hornung, M Deák, J Novák, E Szabó, A Czibula, R Fajka-Boja, Kriston-Pá É, Monostori É, L Kovács
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background and objectives</h3> Secreted, extracellular galectin-1 (exGal-1) but not intracellular Gal-1 (inGal-1) has been described as a strong immunosuppressive protein due to its major activity of inducing apoptosis of activated T-cells. It has previously been reported that T-cells express Gal-1 upon activation; however its participation in T-cell functions has remained largely elusive. To determine the function of Gal-1 expressed by activated T-cells we have carried out a series of experiments. <h3>Methods</h3> Activated T-cells from healthy humans, Gal-1 knock-out and wild-type mice, and Gal-1 transgenic Jurkat (J<sup>Gal</sup>) cells, established in our laboratory, were studied. Furthermore, T-cells were isolated from SLE patients during active disease (n = 20), in remission (n = 10), and healthy controls (n = 20). The expression and localisation of Gal-1 were examined with QPCR, Western blotting, cytofluorimetry or confocal microscopy. Apoptosis was studied in co-culture of PHA-activated T-cells with Gal-1-expressing HeLa tumour cells using fluorescent microscopy. <h3>Results</h3> Both J<sup>Gal</sup>and activated T-cells produced Gal-1. The protein remained intracellularly without secretion. Wild-type mouse and Gal-1 transgenic Jurkat T-cells were significantly more susceptible to the apoptotic effect of exGal-1 than Gal-1 deficient mouse and wild type (Gal-1 non-expressing) Jurkat T-cells. Accordingly, activated T-cells from SLE patients which produced significantly less inGal-1 than the healthy control cells or T-cells from patients in remission after successful immunosuppressive therapy, responded poorly to the apoptotic signal by exGal-1 compared to those of healthy and inactive-lupus T-cells. <h3>Conclusions</h3> We have demonstrated in three independent experimental systems that the <i>de novo</i> expressed Gal-1 in activated T-cells remained intracellularly, confirming that the function of T-cell derived Gal-1 was not the regulation of T-cell viability via an autocrine fashion. Rather, the inGal-1 effectively regulated T-cell apoptosis triggered by environmental exGal-1. Moreover, we showed that low expression of Gal-1 in SLE T-cells resulted in the diminished down regulation of T-cell activity by exGal-1. These results suggested a novel role of inGal-1 in T-cells as a regulator of T-cell response to exGal-1, and its likely contribution to the mechanism in T-cell apoptosis deficiency in lupus.
COMPARISON OF MEDICAL COSTS AVOIDED AMONG NONVALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH DABIGATRAN, RIVAROXABAN, APIXABAN, AND EDOXABAN VERSUS WARFARIN
Authors: Alpesh N. Amin, Amanda Bruno, Jeffrey Trocio, Jay Lin, Melissa Lingohr-Smith
Journal: Journal of the American College of Cardiology (2015)
Bevacizumab Continuation Versus No Continuation After First-Line Chemo-Bevacizumab Therapy in Patients with Metastatic Colorectal Cancer: a Phase 3 Non-Inferiority Trial
Authors: Dieter Koeberle, Daniel Betticher, Roger von Moos, Daniel Dietrich, Peter Brauchli, Daniela Baertschi, Klazien Matter-Walstra, Ralph Winterhalder, Markus Borner, Sandro Anchisi, Peter Moosmann, Attila Kollar, Piercarlo Saletti, Arnaud Roth, Martin Frueh, Marc Kueng, Razvan Popescu, Sabina Schacher, Viviane Hess, Richard Herrmann
Journal: Annals of Oncology (2013)
AB0173 Active anti-VEGF immunization ameliorates collagen induced arthritis
Authors: L. Semerano, E. Assier, E. Duvallet, A. Denys, E. Adam, E. Bernier, G. Grouard-Vogel, M.-C. Boissier
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Synovial neoangiogenesis is a key process in rheumatoid arthritis, contributing to pannus development and maintenance<sup>1</sup>. Anti-angiogenesis treatments targeting the VEGF/VEGF-R system ameliorate arthritis in several animal models<sup>1,2</sup>. Here we report the results of active immunization against VEGF on mice collagen induced arthritis (CIA). Mice were immunized with the VEGF kinoid, a construct of murine VEGF and a carrier protein, the keyhole limpet hemocyanine (KLH), in order to induce a polyclonal anti-VEGF immune response and reduce synovial angiogenesis. <h3>Objectives</h3> To determine: 1) the anti-VEGF immune response elicited by VEGF-K 2) the effect of VEGF-K on mice CIA. <h3>Methods</h3> Forty DBA/1 male mice received 4 intramuscular injections of one of the following: VEGF-K (30-30-5-5μg; 20 mice), KLH (15-15-2.5-2.5μg; 10mice), and PBS (10 mice) as an emulsion with ISA51vg. Three injections were performed before, one after collagen administration. Arthritides were induced by two subcutaneous injections of bovine type II collagen, the first at day 0 in complete Freund adjuvant, the second at day 21 in incomplete Freund adjuvant. All the animals were monitored for clinical scores of arthritis and were sacrificed at day 61. Right forepaws and hind paws were kept for histological analysis. Anti-VEGF antibody (Ab) titers were determined by ELISA. <h3>Results</h3> All VEGF-K treated mice produced anti-VEGF Ab. The VEGF group had lower mean clinical scores of arthritis vs. PBS and KLH groups and significantly lower scores of synovial inflammation (p&lt;0.01) and destruction (p&lt;0.01). In individual mice, moderate correlation between the area under the curve (AUC) of clinical scores and synovial inflammation (r=0.59 p&lt;0.001) and destruction (r=0.54; p&lt;0.0001) was found. <h3>Conclusions</h3> Angiogenesis targeting with active anti-VEGF immunization in CIA results in anti-VEGF Ab production and reduction of synovial inflammation and destruction. <h3>References</h3> Blood vessels, a potential therapeutic target in rheumatoid arthritis? Semerano L, Clavel G, Assier E, Denys A, Boissier MC. Joint Bone Spine. 2011 Mar;78(2):118-23. Peptides targeting inflamed synovial vasculature attenuate autoimmune arthritis. Yang YH, Rajaiah R, Ruoslahti E, Moudgil KD. Proc Natl Acad Sci U S A. 2011 Aug 2;108(31):12857-62. <h3>Disclosure of Interest</h3> L. Semerano: None Declared, E. Assier: None Declared, E. Duvallet: None Declared, A. Denys: None Declared, E. Adam Employee of: Neovacs S.A., E. Bernier Employee of: Neovacs S.A., G. Grouard-Vogel Employee of: Neovacs S.A., M.-C. Boissier Grant/Research support from: Neovacs S.A., Consultant for: Neovacs S.A.
Antioxidants and Atherosclerotic Heart Disease
Authors: Marco N. Diaz, Balz Frei, Joseph A. Vita, John F. Keaney
Journal: New England Journal of Medicine (1997)

Epidemiologic studies have provided evidence of an inverse relation between coronary artery disease and antioxidant intake, and vitamin E supplementation in particular. The oxidative-modification hypothesis implies that reduced atherosclerosis is a result of the production of LDL that is resistant to oxidation, but linking the reduced oxidation of LDL to a reduction in atherosclerosis has been problematic. Several important additional mechanisms may underlie the role of antioxidants in preventing the clinical manifestations of coronary artery disease (Fig. 2). Specifically, there is evidence that plaque stability, vasomotor function, and the tendency to thrombosis are subject to modification by specific antioxidants. For example, cellular antioxidants inhibit monocyte adhesion, protect against the cytotoxic effects of oxidized LDL, and inhibit platelet activation. Furthermore, cellular antioxidants protect against the endothelial dysfunction associated with atherosclerosis by preserving endothelium-derived nitric oxide activity. We speculate that these mechanisms have an important role in the benefits of antioxidants.
P91 Incorporating tuberculosis strain typing data into routine contact tracing investigations: experience from the field
Authors: ML Munang, C Browne, S Khanom, EG Smith, JS Evans, P Hawkey, H Kunst, S Welch, ML Dedicoat
Journal: Thorax (2013)

<h3></h3> Strain typing of tuberculosis (TB) isolates by 24 loci mycobacterial interspersed repetitive unit-variable number tandem repeats (MIRU-VNTRs) is now a routine laboratory tool for TB control, but its utility in informing contact tracing and public health action has not been well reported in the United Kingdom. Since November 2011 we have routinely held typing meetings and undertaken cluster investigation. Over 18 months, 68 clusters were discussed. Fifty-five (81%) clusters were small (2–5 patients), 7 (10%) were medium (6–14 patients) and 6 (9%) were large (&gt;15 patients, median = 42, IQR = 26–52). Enhanced epidemiological investigation was undertaken in 27/68 (40%) clusters. Typing meetings alone readily identified 20 definite epidemiological links between 46/458 (10%) cases. In 15 cases, 9 definite or probable links were not supported by genotyping, leading to expanded screening in one workplace. 112 extended interviews were done. A further 23 definite links between 77 (17%) cases, 2 probable links between 5 (1%) cases and 24 possible links between 72 (16%) cases were found. Expanded screening as a direct result of strain typing and cluster investigation occurred in 4/6 settings where non-household transmission was identified (a factory, 2 places of worship, a hospital, a hostel and a pub). An additional 124 contacts were identified. 65 attended screening, 21 latent TB cases were treated and 1 active TB case was found. Routine incorporation of strain typing data in contact tracing improves diagnosis of latent and active infection but requires investment in data management systems and human resource for enhanced epidemiological investigation.
Concurrent Ossification of Posterior Longitudinal Ligament and Ossification of Ligamentum Flavum in the Thoracic Spine Demonstrated by SPECT/CT Imaging
Authors: Hongyan Yin, Hongcheng Shi
Journal: Clinical Nuclear Medicine (2015)

A 44-year-old man with rectal cancer underwent bone scintigraphy to assess osseous lesions for lower extremity numbness and ambulatory difficulty. Whole-body bone scan showed increased tracer accumulation in the mid thoracic spine. Then SPECT combined with diagnostic CT was performed to further evaluate this doubtful hot spot. According to the images of SPECT/CT, the radiotracer uptake at the site of the T7 to T8 thoracic vertebra was confirmed to be simultaneous ossification of posterior longitudinal ligament complicated with ossification of the ligamentum flavum in the thoracic spine by pathology.
Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.
Authors: M. Ozen, S. Aksoy, O. Dizdar, D. Sener Dede, E. Dogan, C. Arslan, I. H. Gullu, M. K. Altundag
Journal: Journal of Clinical Oncology (2010)

e13664 Background: Fin-HER study showed that addition of nine-weeks of trastuzumab to adjuvant chemotherapy improved disease-free survival and distant disease free survival in operable HER2-positive breast cancer patients. Methods: We studied 102 HER2-positive breast cancer women who have consequently administered our institution between 2007 and 2009 and having adjuvant chemotherapy with nine-weeks of trastuzumab, retrospectively. Immunohistochemically HER2 was 3+ for 83.3% of the cases and 2+ and fluorescence in situ hybridization (FISH) positive for 16.7 % of the cases. Results: Median follow up time was 12 months (range, 3-37). Median age at diagnosis was 49 (range, 24-73). In our series 52 (51%) and 37 (36.3%) of the patients were premenopausal and postmenopausal, respectively. Most of the patients had stage II (46.1%) and III (40.2%). Sixty-three percent of tumors had grade III histology and remaining were grade II. Hormone receptor negative patients were 38%. All patients completed 9 week trastuzumab therapy. 35.3% of patients received 4 cycles of doxorubicin and cyclophosphamide (AC) plus 12 cycles paclitaxel concomitantly with trastuzumab; 30.4% of patients received 4 cyles of AC followed by trastuzumab; 13.7% of patients received 6 cycles docetaxel, doxorubicin, cyclophosphamide (TAC) followed by trastuzumab; 4.9% of patients received 4 cycles docetaxel, cyclophosphamide (TC) followed by trastuzumab and, 4.9% of patients 6 cycles cyclophosphamide, doxorubicin, fluorouracil (CAF) followed by trastuzumab. The remaining patients were treated with other chemotherapy protocols and nine weeks trastuzumab. There were no treatment related deaths. We did not observe any significant cardiotoxicity. No distant metastases were observed for one year median follow up. Only one local recurrence was detected. Conclusions: Although a shorter follow up time, addition of nine weeks of trastuzumab to adjuvant chemotherapy was effective with acceptable toxicity in operable HER2-positive breast cancer patients. No significant financial relationships to disclose.
P1-06-12: Circulating Tumor Cells (CTC) Monitoring during Phase II Study with Lapatinib (L) and Capecitabine (C) in Patients with Brain Metastases from HER2−Positive (+) Metastatic Breast Cancer (MBC) before Whole Brain Radiotherapy (WBR): LANDSCAPE Study.
Authors: J-Y Pierga, C Cropet, P Tresca, F Dalenc, G Romieu, M Campone, Aït-Oukhatar C Mahier, E Le Rhun, A Gonçalves, M Leheurteur, J Domont, M Gutierrez, H Curé, J-M Ferrero, C Labbe-Devilliers, F-C Bidard, T Bachelot
Journal: Cancer Research (2011)

Abstract Background: Decrease of CTC level during treatment in MBC has been reported as an independent prognostic and predictive factor of patients’ outcome. Monitoring CTC in addition to clinical response criteria is currently evaluated in early clinical trials in various cancer types. We sought to evaluate the clinical interest of peripheral blood CTC for patients included in the LANDSCAPE study which assessed the efficacy of upfront systemic treatment with L+C for newly diagnosed brain metastasis. Methods: This analysis is a preplanned secondary endpoint of the LANDSCAPE study. Eligible pts had HER2+ MBC with BM not previously treated with WBR, C or L. Pts received L1250 mg/day and C2000 mg/m2/day, days 1–14, every 21 days. The primary endpoint was a centrally assessed CNS objective response (CNS-OR) defined as a ≥50% volumetric reduction of CNS lesions in the absence of increasing steroid use, progressive neurologic symptoms or progressive extra-CNS disease. CTC were detected in 7.5 ml of blood using the CellSearchSystem™, combining EpCAM immunomagnetic selection (IMS) followed by anti-cytokeratin (A45B/B3) fluorescently staining for CTC at baseline and at day (D) 21, before cycle 2. Results: From 04/2009 to 08/2010, 45 pts were enrolled, 41 were evaluable for CTC at baseline and 38 at D21. Median age was 56 (range 35 to 79). PS was &amp;gt;1 only in 2 pts. At baseline, 20/41 (48.8%) pts had ≥ 1CTC and 9 (22%) ≥ 5CTC (range 1–301, median 3). CTC were detected in pts with (18/37) or without disease outside SNC (2/6) (p=0.63). At a median follow-up of 10 months (range 2.9−16.5), median TTP was 6.0 months [95% CI 4.9; 7.4] vs. 4.3 [2.8; 5.9] months for pts without and with CTC at baseline respectively (p=0.14). After 21 days of treatment, a disappearance of CTC was observed in 11pts (31%). At D21, only 7 (18.4%) pts had ≥ 1CTC and 3 (8%) ≥ 5 CTC (p=0.006, D21 vs. baseline). In 43 evaluable pts, CNS-OR rate was 67% (95%CI 51–81), with a median time from inclusion to response of 1.8 month. Absence of CTC was not correlated with CNS-OR rate at baseline (17/21 (81%) vs. 11/19 (58%), NS). Strikingly, remaining positivity for CTC at D 21 (≥ 1CTC) was correlated with a poor response rate in CNS: 2/6 (33.3%) vs. 25/31 (80.6%) in pts with 0 CTC, p=0.03. Conclusions: Early decrease (at D 21) in CTC level is correlated with a high response rate in newly diagnosed BM to L + C and underlines the predictive value of this blood marker in MBC pts even for brain metastasis. Longer follow-up is needed to assess its prognostic value under antiHER2 targeted therapy. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-06-12.
Urinary Muramidase and Renal Disease
Authors: John P. Hayslett, Pasquale E. Perillie, Stuart C. Finch
Journal: New England Journal of Medicine (1968)

Muramidase appeared in the urine of 80 healthy adults and 51 patients with acute or chronic leukemia, all without clinical evidence of renal disease, only when the serum muramidase concentration exceeded approximately three times the control level, demonstrating an apparent renal threshold for excretion of the enzyme. Similar determinations in 73 patients with renal disease or conditions known to affect the kidney in whom histologic examination of kidney tissue was also made indicated muramidase activity in the urine that correlated well with histologic evidence of damage to renal tubules. These observations are consistent with the suggestion that the appearance of the enzyme in the urine is due to reduced tubular reabsorption of filtered enzyme from the urine. Measurement of urinary muramidase may be a useful diagnostic index of renal tubular injury when serum values do not exceed the renal threshold.
Case 39-1985
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, Betty U. McNeely, Neil R. Blacklow, John S. Wolfson
Journal: New England Journal of Medicine (1985)

Presentation of CaseA six-year-old girl was admitted to the hospital because of vomiting and diarrhea.She was in excellent health until early July, three days before admission, when she began to vomit all oral intake. A low-grade fever appeared. Two days before admission abdominal cramps developed, occurred at intervals of approximately one hour, and were often followed by vomiting. One day before entry the temperature rose to 38.2°C. Diarrhea occurred, with the passage of dark-brown, watery stools that were not foul and did not contain frank blood or mucus. The patient complained of myalgia, was profoundly weak, and showed . . .
Thrombendarterectomy in the Treatment of Acute Thrombosis of the Femoral and Popliteal Arteries
Authors: Paul F. Gryska
Journal: New England Journal of Medicine (1959)

THE extensive clinical experience now reported has demonstrated the value of a surgical approach in the management of peripheral arterial diseases. The use of bypass procedures by Crawford et al.1 and by Linton and Menendez2 has been very successful. Similarly, Cannon, Barker and Kawakami.3 Muller, Liddle and Edmunds4 and Wylie and Gardener5 have shown thrombendarterectomy to be a useful tool in arterial occlusive disease.Except for 3 cases presented by Shaw6 most reported experiences have been in patients with chronic femoropopliteal occlusion. Little consideration has been given to acute arterial insufficiency due to thrombosis in atherosclerotic arteries.The pathologic changes . . .
Scientists Gain Insight Into Cancer Gene Relationships
Authors: E. Blume
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Scientists Gain Insight Into Cancer Gene Relationships Get access Elaine Blume Elaine Blume Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 17, 1 September 1993, Pages 1373–1374, https://doi.org/10.1093/jnci/85.17.1373 Published: 01 September 1993
Long-term treatment follow-up of children with sickle cell disease monitored with abnormal transcranial Doppler velocities
Authors: Françoise Bernaudin, Suzanne Verlhac, Cécile Arnaud, Annie Kamdem, Isabelle Hau, Emmanuella Leveillé, Manuela Vasile, Florence Kasbi, Fouad Madhi, Christine Fourmaux, Sandra Biscardi, Eliane Gluckman, Gérard Socié, Jean-Hugues Dalle, Ralph Epaud, Corinne Pondarré
Journal: Blood (2016)